BillionToOne Inc.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma	pancreatic ductal adenocarcinoma	Recruiting	Phase 2	2026-09-21	NCT07096362
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment	22q11.2 deletion syndrome, Abnormalities, Multiple, Cardiovascular Abnormalities, Chromosome Aberrations, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, DiGeorge syndrome, Down syndrome, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Musculoskeletal Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sex Chromosome Aberrations, Trisomy 18 Syndrome, aneuploidy, cardiovascular disorder, chromosomal disorder, congenital heart disease, endocrine system disorder, heart disorder, hereditary disease, hypoparathyroidism, intellectual disability, lymphatic system disorder, musculoskeletal system disorder, nervous system disorder, parathyroid gland disorder, trisomy 13, trisomy 18	Recruiting	Not stated	2026-06-12	NCT07643896
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	gastroesophageal adenocarcinoma	Recruiting	Phase 1	2026-03-10	NCT05733689

Clinical trials